CD274 and neoplasm: Targeting TGFB has indeed enhanced tumor susceptibility to anti-PD-1/PD-L1 therapies [28, 48, 49], which promises to be an effective strategy that may have good prospects for the treatment of pMMR/MSS CRCs.